Changes in Hong Kong stocks | Innovative pharmaceutical stocks continue to rise, and many important data will be announced by ESMO and platform-based BDs will be implemented one after another to convey confidence

The Zhitong Finance App learned that innovative pharmaceutical stocks continued to rise. As of press release, Zaiding Pharmaceutical (09688) rose 6.26% to HK$20.04; Genting Xinyao (01952) rose 5.62% to HK$35.7; Yingen Biotech (09606) rose 5.28% to HK$177.50; and Kangfang Biotech (09926) rose 3.94% to HK$95.

According to news, the 2026 European Society of Medical Oncology (ESMO) Annual Meeting will be held in Madrid on October 23-27. A total of 29 domestically produced innovative drug studies were selected for the LBA as a breakthrough summary, accounting for about one-third of the total LBA. 5 projects entered the Chairman's seminar, covering cutting-edge tracks such as ADC, dual antibodies, and targeted drugs. A number of Hong Kong stock innovative drug companies will disclose key Phase III clinical data.

Furthermore, the recent implementation of platform-based BDs continues to convey confidence. On October 19, Hanson Pharmaceuticals announced that it had once again reached a multi-project strategic cooperation with ADC, with a total down payment and first-year annual payment of $510 million, with potential milestone payments exceeding US$15 billion. On the same day, Jietai Technology announced that it had reached a cooperation with Eli Lilly on an AI-driven extra-hepatic LNP delivery platform, with a down payment of over US$10 million, with a total of up to US$1.1 billion. Guojin Securities believes that innovative drug companies have arrived at a loss turning point, and clinical data is being concentrated throughout the year. In addition, overseas clinical trials are progressing smoothly with the BD overseas pipeline, and they are optimistic about investment opportunities in the innovative drug sector.